期刊文献+

紫癜清颗粒对HSP患者CD4^+ CD25^+ Tregs细胞的影响 被引量:1

原文传递
导出
摘要 目的探讨紫癜清颗粒对过敏性紫癜(HSP)患者的临床疗效及外周血CD4+CD25+调节性T细胞、其转录因子FOXP3表达的影响。方法纳入60例确诊为HSP患者,随机分为两组,治疗组予以紫癜清颗粒(A组),对照组予以激素联合抗组胺药物(B组);两周为1个疗程,共观察4周,随访半年,采用流式细胞术检测外周血CD4+CD25+Treg、转录因子FOXP3的表达,同期选10例健康人作为正常对照。结果治疗组有效率与对照组相当(P>0.05),但复发率较对照组减低(P<0.01);A、B组治疗前外周血CD4+CD25+Treg及CD4+CD25+FOXP3+表达比例较健康对照组明显降低(P<0.01);紫癜清颗粒治疗后患者外周血CD4+CD25+Treg及CD4+CD25+FOXP3+比例增高,与对照组治疗后患者外周血CD4+CD25+Treg及CD4+CD25+FOXP3+的表达相比,无统计学意义(P>0.05),但表达比例较对照组高。结论 1治疗组总有效率为93.33%,对照组总有效率为96.66%,说明中药汤剂紫癜清颗粒与西医传统治疗方案激素联合抗组胺药物疗效相当,但其复发率及临床副作用较西药治疗都明显减少;2A、B组治疗前CD4+CD25+Treg的表达低于正常,说明调节性T细胞可能参与了HSP的发病,而治疗后CD4+CD25+Treg及CD4+CD25+FOXP3+的表达增高,可能是紫癜清颗粒治疗HSP有效的原因。
出处 《时珍国医国药》 CAS CSCD 北大核心 2015年第10期2380-2382,共3页 Lishizhen Medicine and Materia Medica Research
基金 黑龙江省自然科学基金(No.D201153) 黑龙江中医药管理局科研项目(No.ZHY10-Z41)
  • 相关文献

参考文献9

  • 1Asano M,Toda M, Sakaguchi N, et al. Autoimmune disease as a conse- quence of developmental abnormality of a T cell sub - population [ J ]. J Exp Med,1996,184(2) :387.
  • 2Belkaid Y, Rouse BT, Natural regulatory T cells in infectious disease [ J]. Nat Immunol,2005,6(4) :353.
  • 3刘萍,张秋业.儿童过敏性紫癜急性期Th17细胞功能和CD4^+CD25^+调节性T细胞水平变化[J].齐鲁医学杂志,2012,27(1):31-33. 被引量:9
  • 4Salomon B,Lenschow DJ, Rhee L, et al. B7/CD28 costimulation is es- sential for the homeostasis of the CD4 + CD25 + immuno regulatory T cells that control autoimmune diabetes [ J ]. Immunity, 2000, 12 ( 4 ) : 431.
  • 5Orwitz DA,Zheng SG, Gray DG. The role of combination of IL - 2 and TGF - beta or IL - 10 generation an function of CD4 + CD25 + and CD8 + regulatory T cell subsets [ J ]. J Leukoc Biol,2003,74 (4) :471.
  • 6Littman DR, Rudensky A. Thl7 and regulatory T cells in mediating and restraining inflammation[ J]. Cell ,2010,140(6) :845.
  • 7Onishi Y, Fehervari Z,Yamaguchi T, et al. FOXP3 + natural regulatory T eells preferentially form aggregates on dendritic cells in ritro and ae- tively inhibit their maturation [ J]. Proc Natl Aead Sei USA,2008,105 (29) :10113.
  • 8陈祚珈,高雅懿,李志远,李斌.FOXP3^+调节性T细胞[J].生命科学,2010,22(6):515-528. 被引量:24
  • 9雍彦礼,孙凤,王金环,郝晶.孙伟正教授治疗过敏性紫癜经验总结[J].时珍国医国药,2014,25(9):2271-2272. 被引量:6

二级参考文献124

  • 1Basu S, Golovina T, Mikheeva T, et al. Cutting edge: Foxp3- mediated induction of pim 2 allows human T regulatory cells to preferentially expand in raparnycin. J Immunol, 2008, 180(9): 5794-8.
  • 2Strauss L, Whiteside TL, Knights A, et al. Selective survival of naturally occumng human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol, 2007, 178(1): 320-9.
  • 3Liu G, Bums S, Huang G, et al. The receptor S1P1 overrides regulatory T cell-mediated immune suppression through AktmTOR. Nat Immunol, 2009, 10(7): 769-77.
  • 4Sawicka E, Dubois G, Jarai G, et al. The sphingosine 1- phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+/CD25+ T-regulatory cells and enhances their functional activity. J Immunol, 2005, 175 02): 7973-80.
  • 5Wang L, Tao R, Hancock WW. Using histone deacetylase inhibitors to enhance Foxp3+ regulatory T-cell function and induce allograft tolerance. Immunol Cell Biol, 2009, 87(3): 195-202.
  • 6Webster KE, Wakers S, Kolhler RE, et al. In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J Exp Med, 2009, 206(4): 751- 60.
  • 7Luo X, Tarbell KV, Yang H, et al. Dendritic ceils with TGF- betal differentiate naive CD4+CD25 T cells into islet-protective Foxp3+ regulatory T cells. Proc Natl Acad Sci USA, 2007, 104(8): 2821-6.
  • 8Mason D, Powrie F. Control of immune pathology by regulatory T cells. Curr Opin Immumd 1998.10 (6): 649-55.
  • 9Hori S, Carvalho TL, Demengeot J. CD25+CD4+regulatory T cells suppress CD4+ T cell-mediated pulmonary hyperinflammation driven by Pneumocystis carinii in im- munodeficient mice. Eur J Immunol, 2002, 32(5): 1282-91.
  • 10Montagnoli C, Bacci A, Bozza S, et al. B7/CD28-dependent CD4+CD25+ regulatory T cells are essential components of the memory-protective immunity to Candida albicans. J Immunol, 2002, 169(11): 6298-308.

共引文献36

同被引文献9

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部